Introduction:
Cambridge-based Metrion Biosciences Ltd has secured £3.5m in new equity financing – led by Maven Capital Partners and a £1m contribution from existing investor, Gresham House Ventures. The funding will be used to expand Metrion’s new laboratories in Cambridge, UK, invest in specialist equipment, and enhance the company’s global marketing activities. Metrion Biosciences is a specialist ion-channel contract research organization (CRO) and drug discovery business.
- Metrion Biosciences has secured £3.5m in new equity financing.
- The funding will be used to expand Metrion’s new laboratories in Cambridge, UK, invest in specialist equipment, and enhance the company’s global marketing activities.
- Metrion Biosciences is a specialist ion-channel contract research organization (CRO) and drug discovery business.
- Dr David Milroy has joined the board as Maven’s investor director, and Steve Carle has replaced Maya Ward as Gresham’s board representative.
- Dr Marc Rogers, Dr Barry Kenny, and Mark Keogh have retired as non-executive directors of the company.
Conclusion:
With the new equity financing, Metrion Biosciences will be able to expand its Cambridge laboratories, invest in specialized equipment, and enhance its global marketing activities. The funding will support the company’s mission as a specialist ion-channel contract research organization and drug discovery business. The new board changes indicate a shift in leadership and strategic direction. Overall, this financing is a significant milestone for Metrion Biosciences and positions the company for future growth and success in the biomedical research industry.
